rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    BIAF
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      BioAffinity Technologies reports record CyPath Lung test performed in October
      Nov 11Yahoo FinanceBIAF
      bioAffinity Technologies posts record monthly volume for CyPath Lung test

      bioAffinity Technologies Inc (NASDAQ:BIAF) recorded 235 CyPath Lung tests in October, the highest monthly volume for its noninvasive lung cancer test. The total is up 29% from October 2025 and equals about 45% of all tests performed in the third quarter of 2026, according to the company. The...

      Nov 11Yahoo FinanceBIAF
      bioAffinity posts record month for CyPath Lung cancer test
      Nov 11Yahoo FinanceBIAF
      bioAffinity Technologies Reports Record Monthly Testing Volume in October for Its Noninvasive CyPath® Lung Test

      SAN ANTONIO, November 11, 2026--bioAffinity reports record monthly testing volume for the Company's noninvasive lung cancer test CyPath Lung.

      Nov 11Yahoo FinanceBIAF
      bioAffinity Technologies earnings beat by $25.61, revenue fell short of estimates
      Nov 6Investing.comBIAF
      bioAffinity Technologies to Present New Perspectives on CyPath® Lung’s Use for Cancer Risk Assessment at CHEST 2026
      Oct 15Yahoo FinanceBIAF
      bioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026
      Oct 13Yahoo FinanceBIAF
      bioAffinity Technologies Completes New $4 Million Financing

      Detailed price information for Bioaffinity Technologies Inc (BIAF-Q) from The Globe and Mail including charting and trades.

      Oct 10The Globe and MailBIAF
      WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
      Oct 9MorningstarBIAF
      BioAffinity Technologies Closes $4 Million Direct Offering, Private Placement
      Oct 9Yahoo FinanceBIAF
      bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

      SAN ANTONIO, October 09, 2026--BIAF announces closing of $4 million registered direct financing of common stock and private placement priced at-the-market under Nasdaq rules

      Oct 9Yahoo FinanceBIAF
      WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
      Oct 8MorningstarBIAF
      BioAffinity Technologies Prices $4 Million Registered Direct Offering
      Oct 8Yahoo FinanceBIAF
      bioAffinity Technologies Receives Japanese Patent Allowance for CyPath Lung AI Diagnostic Test
      Oct 8Yahoo FinanceBIAF
      bioAffinity Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath® Lung and AI-Built Algorithm
      Oct 8Yahoo FinanceBIAF
      Update: BioAffinity Technologies Prices $4 Million Registered Direct Offering
      Oct 8Yahoo FinanceBIAF
      bioAffinity Technologies Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026

      SAN ANTONIO, October 06, 2026--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced that sales of its CyPath® Lung test for lung cancer increased more than 100% through the third quarter of 2026 compared to 2025, reflecting continued growth in clinical adoption of the Company’s noninvasive test for assessing the likelihood of lung cancer in high-risk indivi

      Oct 6Yahoo FinanceBIAF
      bioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL
      Sep 30Yahoo FinanceBIAF
      bioAffinity Technologies Builds Momentum for Non-Invasive Lung Cancer Detection

      bioAffinity Technologies (NASDAQ:BIAF) is continuing to build momentum behind its non-invasive lung cancer diagnostic, CyPath Lung, with new clinical evidence and an expanding route into the US federal healthcare market. The company is presenting real-world clinical cases and new research focused on veteran and military populations at the 2026 NAVREF Annual Conference, highlighting the potential role of CyPath Lung in helping physicians make more informed diagnostic decisions.

      Sep 28Yahoo FinanceBIAF
      bioAffinity Technologies to Showcase Lung Cancer Test Data at Veterans’ Research Conference

      bioAffinity Technologies (NASDAQ:BIAF) will present new clinical findings on its noninvasive lung cancer test, CyPath® Lung, at the 2026 NAVREF Annual Conference, running September 27–30 in Arlington, Virginia. The company is set to unveil two posters focused on the test’s use in veteran and military healthcare settings.

      Sep 22Yahoo FinanceBIAF
      BioAffinity Technologies Stock Surges Following Hong Kong Patent Grant
      Sep 17BenzingaBIAF
      12 Health Care Stocks Moving In Thursday's Intraday Session - Aethlon Medical (NASDAQ:AEMD), bioAffinity

      Gainers Aethlon Medical (NASDAQ:AEMD) shares rose 330.8% to $6.16 during Thursday's regular session. The market value of their outstanding shares is at $1.0 million. bioAffinity Technologies (NASDAQ:BIAF) shares

      Sep 17BenzingaAEMDBIAF
      bioAffinity Technologies Secures Hong Kong Patent for CyPath Lung Cancer Diagnostic

      The new patent extends intellectual property protection for the company’s noninvasive lung cancer detection technology in Asia, complementing its existing Chinese patent. Key Investor TakeawaysbioAffinity Technologies (NASDAQ:BIAF) has received a Hong Kong patent covering core technology used in its CyPath Lung diagnostic test.

      Sep 17Yahoo FinanceBIAF
      bioAffinity Technologies Announces Grant of Hong Kong Patent for Company's CyPath® Lung Noninvasive Lung Cancer Diagnostic

      SAN ANTONIO, September 17, 2026--bioAffinity announces new Hong Kong patent that protects the proprietary technology behind its noninvasive CyPath Lung diagnostic for lung cancer.

      Sep 17Yahoo FinanceBIAF
      bioAffinity Technologies Highlights Investor Presentation at Conference

      Detailed price information for Bioaffinity Technologies Inc (BIAF-Q) from The Globe and Mail including charting and trades.

      Sep 12The Globe and MailBIAF
      bioAffinity Technologies at H.C. Wainwright conference: lung test gains traction
      Sep 11Investing.comBIAF
      bioAffinity Regains Nasdaq Compliance, Maintains Capital Market Listing

      Detailed price information for Bioaffinity Technologies Inc (BIAF-Q) from The Globe and Mail including charting and trades.

      Sep 10The Globe and MailBIAF
      bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements

      SAN ANTONIO, September 09, 2026--bioAffinity Technologies received notice that it has regained compliance with Nasdaq's applicable listing requirements.

      Sep 9Yahoo FinanceBIAF
      bioAffinity’s AI Lung-Cancer Stock Jumped Nearly 48% After a Reverse Split. What Would Have to Go Right?

      bioAffinity Technologies jumped 47.95% on September 2, one day after announcing that it was advancing the potential use of CyPath Lung for post-treatment surveillance of lung-cancer patients. The move followed a 1-for-15 reverse split that became effective for trading on August 24, a combination that can produce dramatic percentage swings in a thinly traded stock. […]

      Sep 5Yahoo FinanceBIAF
      bioAffinity Technologies to Present Corporate Update at Conference

      Detailed price information for Bioaffinity Technologies Inc (BIAF-Q) from The Globe and Mail including charting and trades.

      Sep 4The Globe and MailBIAF
      bioAffinity Technologies to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

      SAN ANTONIO, September 03, 2026--BIAF President and CEO Maria Zannes will present a corporate update at the H.C. Wainwright 28th Annual Global Investment Conference Sept. 14-16.

      Sep 3Yahoo FinanceBIAF
      bioAffinity Technologies Shares Rise After CyPath Lung Surveillance Update

      bioAffinity Technologies (NASDAQ:BIAF) shares rose 39. 4% in premarket trading after the company announced that its CyPath® Lung noninvasive diagnostic test is now positioned for post-curative surveillance of lung cancer recurrence.

      Sep 3Yahoo FinanceBIAF
      Why is bioAffinity Technologies stock surging today?
      Sep 3Investing.comBIAF
      12 Health Care Stocks Moving In Wednesday's Intraday Session
      Sep 2BenzingaBIAF
      BioAffinity Technologies Stock Skyrockets Wednesday: What's Happening?
      Sep 2BenzingaBIAF
      Why Is bioAffinity Technologies Stock Trading Higher Today? - bioAffinity Technologies (NASDAQ:BIAF)
      Sep 1BenzingaBIAF
      12 Health Care Stocks Moving In Tuesday's Intraday Session
      Sep 1BenzingaBIAF
      bioAffinity Technologies Advances CyPath Lung for Post-Treatment Lung Cancer Surveillance

      The company is evaluating an additional application for CyPath Lung that could complement CT imaging when monitoring lung cancer survivors for recurrence or new primary cancers. Key Investor TakeawaysbioAffinity Technologies (NASDAQ:BIAF) is advancing CyPath Lung for potential use in post-treatment lung cancer surveillance, expanding its focus beyond early detection.

      Sep 1Yahoo FinanceBIAF
      12 Health Care Stocks Moving In Tuesday's Pre-Market Session
      Sep 1BenzingaBIAFINBS
      bioAffinity Technologies Advances CyPath® Lung for Surveillance of Lung Cancer Survivors

      SAN ANTONIO, September 01, 2026--bioAffinity Technologies is advancing the application of its CyPath Lung test for surveillance of lung cancer patients who have completed treatment.

      Sep 1Yahoo FinanceBIAF

      This is the newest page. Registered accounts read further back.